Eli Lilly Price Target Raised to $1612.00/Share From $1376.00 by Truist Securities

What happened

Truist Securities raised its price target on Eli Lilly shares to $1612.00 per share from $1376.00 per share, according to a Benzinga ratings report.

Confirmed

Global impact / market context

A higher price target signals the analyst expects more future value from Eli Lilly, which can pull investor attention toward the drugmaker and support demand for its shares relative to other holdings.

Analyst inference

Price target changes are analyst views, not company results. This upgrade reflects Truist's own outlook and does not by itself change Eli Lilly's drug sales, costs, or cash available.

Analyst inference

What to watch

1. Truist Securities raised its price target on Eli Lilly to $1612.00 per share from $1376.00 per share, per the Benzinga ratings report. Confirmed
2. Watch whether Eli Lilly's management gives sales and profit guidance that supports Truist's higher target when the company next reports results. Proposed
3. Watch whether other analysts follow Truist and raise their own targets, which could strengthen investor demand for Eli Lilly shares. Analyst inference

Evidence

• Original source link unavailable